Related Experiment Video

Updated: Jul 10, 2025

Discovery of Driver Genes in Colorectal HT29-derived Cancer Stem-Like Tumorspheres
06:52

Discovery of Driver Genes in Colorectal HT29-derived Cancer Stem-Like Tumorspheres

Published on: July 22, 2020

6.6K

STAT2 Controls Colorectal Tumorigenesis and Resistance to Anti-Cancer Drugs

Mircea T Chiriac1,2, Zsuzsanna Hracsko1, Christoph Becker1,2

  • 1Department of Medicine 1, Gastroenterology, Endocrinology and Pneumology, University Hospital Erlangen, University of Erlangen-Nuremberg, 91054 Erlangen, Germany.

Cancers
|November 25, 2023
PubMed

Insights

Signal transducer and activator of transcription 2 (STAT2) promotes colorectal cancer (CRC) development. Targeting STAT2-dependent signaling may offer new therapeutic strategies for CRC patients.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • Colorectal cancer (CRC) presents a substantial global health challenge.
  • The precise role of signal transducer and activator of transcription 2 (STAT2) in CRC pathogenesis remains unclear.
  • Current therapeutic strategies do not specifically target STAT2-dependent signaling pathways.

Purpose of the Study:

  • To elucidate the function of STAT2 in the development and progression of colorectal cancer.
  • To evaluate the potential of targeting STAT2 as a therapeutic strategy for CRC.

Main Methods:

  • Utilized experimental mouse models of CRC, incorporating both inflammation-driven and independent pathways.
  • Employed RNA-sequencing (RNA-Seq) for transcriptomic analysis.
  • Conducted functional assays using three-dimensional (3D) tumoroids treated with various anti-cancer agents.

Main Results:

  • Mice lacking STAT2 (Stat2 mice) exhibited increased resistance to CRC development.
  • Tumoroids derived from Stat2 mice showed delayed growth, reduced size, and enhanced differentiation compared to controls.
  • Tumoroids from Stat2 mice demonstrated heightened susceptibility to anti-cancer agents, leading to increased cell death.

Conclusions:

  • STAT2 actively promotes colorectal cancer progression.
  • Targeting STAT2-mediated signaling pathways represents a promising novel therapeutic avenue for CRC treatment.
Keywords:
ApcMin/+STAT2anti-cancer therapycolorectal cancer mouse modeltumoroid

More Related Videos

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

13.8K
In vitro Organoid Culture of Primary Mouse Colon Tumors07:33

In vitro Organoid Culture of Primary Mouse Colon Tumors

Published on: May 17, 2013

35.1K

Related Concept Videos

Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
7.4K
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.3K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.8K
Loss of Tumor Suppressor Gene Functions01:12

Loss of Tumor Suppressor Gene Functions

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...
4.8K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K